Treeline Biosciences outlined plans to go public through a reverse merger with Standard BioTools, with the combined company expected to trade on Nasdaq under the Treeline Biosciences name. The transaction is structured to give Treeline investors the majority stake and provide Standard shareholders with a contingent value right tied to value extraction from Standard’s pre-merger assets. Treeline said the combined company would have nearly $900 million in cash expected to fund operations into 2029, supporting development of a diversified oncology pipeline in early clinical stages. The company is led by Josh Bilenker, and its disclosed candidates target multiple cancer pathways including BCL6 and KRAS. For capital markets, the deal reflects how cash-rich, long-runway biotech narratives are finding public-market access even when classic IPO routes remain difficult for early-stage programs.